3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
6
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
41
Recurrence
14
Prostatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Vomiting
1
Vascular Diseases
1
Paraproteinemias
1
Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Plasma Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Hemostatic Disorders
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Blood Coagulation Disorders
1
Interventions
nilotinib
4
Imatinib Mesylate
4
Dasatinib
4
troxacitabine
1
ponatinib
1
litronesib
1
exatecan
1
carfilzomib
1
bosutinib
1
blinatumomab
1
asciminib
1
TAK-901
1
STA 9090
1
Panobinostat
1
Homoharringtonine
1
Fentanyl
1
Dexamethasone
1
Decitabine
1
Calcium Dobesilate
1
2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Blast Crisis
×
Calcium Dobesilate
×
Clear all
NCT01204164
2016-05-06
TG02-101
Tragara Pharmaceuticals, Inc.
Phase 1
Completed
120 enrolled